Iris Roth, Ph.D.

Iris Roth, Ph.D.

Former Chief Operating OfficeratZentalis Pharmaceuticals· In the 2023 proxy

Pay in FY2023Zentalis Pharmaceuticals stock -24.8% the same year

Iris Roth, Ph.D. was paid $5.9M in FY2023 (Dec). Zentalis Pharmaceuticals stock fell 24.8% that year.

Pay$100 in the stock at the end of FY22 → $75
Pay is from the Summary Compensation Table of each Zentalis Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zentalis PharmaceuticalsPublic company · 3 yr
    • Former Chief Operating Officer2023 – Present · 3 yrStock in role -89%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?